Incontinence News and Research

Latest Incontinence News and Research

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.

19 Apr 2010

Prostate cancer patients having robotic prostatectomy enjoy significant benefits: Study

A new study of almost 700 patients from The Mount Sinai Medical Center shows that prostate cancer patients who had robotically assisted prostatectomy enjoyed significant benefits over patients who had a traditional open radical prostatectomy, including decreased surgical and recovery time, less blood loss during surgery and significantly shorter hospital stays.

16 Apr 2010

Trans-urethral prostate hyperthermia treatment offers 100% response rate

According the Dr. Friedrich Douwes, Medical Director of St. George Hospital in Bad Aibling, Germany, president of the German Oncological Society and the author of several hundred scientific articles and books, trans-urethral prostate hyperthermia has a 100% initial response rate.

16 Apr 2010

Contura submits PMA for Aquamid

Contura Inc. has submitted a Premarket Approval Application for Aquamid to the U.S. Food and Drug Administration requesting marketing approval in the U.S. for the aesthetic treatment of moderate to severe facial wrinkles and folds.

16 Apr 2010

NAFC holds free educational webinar for seniors who live with incontinence

The National Association For Continence is holding a free educational webinar, Nocturia: Risk Factors for Falls & Fractures and Nighttime Fall Prevention Strategies, on Tuesday, April 20 at 8 p.m. (EST). This event will benefit seniors who live with incontinence and their caregivers.

13 Apr 2010

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Oceana Therapeutics and Q-Med AB today announced the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for Solesta® for the treatment of Fecal (or Bowel) Incontinence, a largely unsatisfied medical need afflicting millions of Americans.

12 Apr 2010

PSA test distress, study urges caution

A new study wants men to be informed about risks associated with screening for prostate cancer. The research has brought out that the prostate cancer tests can cause significant psychological distress to the men undergoing the screening. 330 men were studied by the University of Bristol as they underwent the tests and after they finished.

9 Apr 2010

ANA recognizes WOC nursing as specialty

Wound, Ostomy and Continence nursing is one of the newest specialties recognized by the American Nurses Association. The Wound, Ostomy & Continence Nurses Society was recently notified of the ANA's decision.

8 Apr 2010

Dutasteride may help reduce risk of developing prostate cancer, say researchers

A drug already used to shrink benign, enlarged prostates could also help to reduce the risk of developing prostate cancer, according to researchers in the US.

8 Apr 2010

New study to compare Botox against oral medications for urge incontinence in women

A new study is underway at Loyola University Health System to compare botulinum toxin A or Botox® versus common oral medications for urge incontinence in women. Urge incontinence is urinary incontinence with a strong or sudden need to urinate. Millions of women suffer in silence each day from this condition.

6 Apr 2010

Clinical utility and pharmacological action of MN-166 in treatment of MS

MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).

3 Apr 2010

NAFC supports PMAA of Uromedica's ACT device for SUI, speaks to FDA

On March 24, Nancy Muller, executive director of The National Association For Continence (NAFC), spoke to the Food and Drug Administration (FDA), in support of a Premarket Approval Application (PMAA) of Uromedica, Inc.'s Adjustable Continence Therapy (ACT®) device to approve its usage in the U.S. The ACT is designed to treat female stress urinary incontinence (SUI).

2 Apr 2010

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.

2 Apr 2010

Attends completes successful recapitalization: KPS

KPS Capital Partners, LP announced today that its portfolio company Attends Healthcare, Inc. has completed a successful recapitalization. Attends raised $98 million of new financing, including a $20 million asset-based revolving credit facility and $78 million in term loans.

1 Apr 2010

WOCN Society launches campaign to raise awareness about benefits of specialized care

Patients and families who are dealing with conditions such as non-healing wounds, bedsores, bladder and bowel incontinence and ostomy-related issues contend with physical symptoms, as well as social and emotional side effects. The impact on patients and families can exact an enormous toll. The Wound Ostomy & Continence Nurses Society is launching a campaign to raise awareness about the benefits of specialized care.

31 Mar 2010

'Because Life is for Living' campaign launched to raise awareness about brachytherapy

Former England Rugby World Cup winner Matt Dawson today launched the 'Because Life is for Living' campaign to raise awareness about brachytherapy, a very precise and highly effective form of radiotherapy to treat cancer.

30 Mar 2010

Fecal incontinence: Sacral nerve stimulation along with Medtronic InterStim Therapy promising

Data published in the March issue of the Annals of Surgery show that investigational use of sacral nerve stimulation with Medtronic InterStim® Therapy reduces fecal incontinent episodes and increases quality of life in patients with the condition. The 120-patient, multi-center study - the largest trial of its kind in the world and the first such trial in North America - examined the efficacy of InterStim Therapy in patients with chronic fecal incontinence who had failed or were not candidates for more conservative treatments.

30 Mar 2010

USPTO allows Pisgah Labs' patent application regarding imipramine pamoate

Pisgah Labs, a drug product development company and an active pharmaceutical ingredient manufacturer (API) located in western North Carolina, has received a patent allowance in a series of patent applications. The US Patent & Trademark Office (USPTO) has notified Pisgah Labs, Inc. that a patent application related to a therapeutically significant family of pharmaceutical polymorphic compositions of imipramine pamoate has been allowed. The patent application also includes methods of manufacturing, purifying and use in pharmaceutical preparations.

26 Mar 2010

Beaumont Hospital opens women's urology center

It’s something that women don’t talk about even to their best friends or their doctors. That’s why Beaumont Hospitals has created a new Women’s Urology Center offering leading-edge treatments, innovative research and the most advanced minimally invasive procedures for women’s urological conditions such as incontinence, pelvic pain and sexual dysfunction.

25 Mar 2010

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fourth quarter and full year ended December 31, 2009.

25 Mar 2010

Incontinence News and Research

Latest Incontinence News and Research

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Prostate cancer patients having robotic prostatectomy enjoy significant benefits: Study

Trans-urethral prostate hyperthermia treatment offers 100% response rate

Contura submits PMA for Aquamid

NAFC holds free educational webinar for seniors who live with incontinence

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

PSA test distress, study urges caution

ANA recognizes WOC nursing as specialty

Dutasteride may help reduce risk of developing prostate cancer, say researchers

New study to compare Botox against oral medications for urge incontinence in women

Clinical utility and pharmacological action of MN-166 in treatment of MS

NAFC supports PMAA of Uromedica's ACT device for SUI, speaks to FDA

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

Attends completes successful recapitalization: KPS

WOCN Society launches campaign to raise awareness about benefits of specialized care

'Because Life is for Living' campaign launched to raise awareness about brachytherapy

Fecal incontinence: Sacral nerve stimulation along with Medtronic InterStim Therapy promising

USPTO allows Pisgah Labs' patent application regarding imipramine pamoate

Beaumont Hospital opens women's urology center

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Incontinence News and Research

Latest Incontinence News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in